Senior J&J head appointed by Synageva

pharmafile | September 23, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing J&J, JJ, rob bazemore, synageva 

US biopharma firm Synageva has appointed Robert Bazemore as its chief operating officer.

Reporting directly to the president and chief executive of Synageva – Sanj Patel – Bazemore will oversee the launch of the company’s lead programme and will have responsibility for the its commercial, market access and medical affairs operations.

Bazemore has over 22 years of biopharma experience, with the last 12 years being spent at Johnson & Johnson in various roles including vice president, Ethicon New Growth Platforms and president of its Janssen Biotech unit.

Bazemore began his career at J&J in 2002 and held numerous senior commercial positions, having led the worldwide immunology portfolio strategy and the launches of multiple new products and indications.

“Rob is a seasoned biopharmaceutical executive with substantial commercial leadership experience and his proven track record launching global products makes him a valuable addition to the team,” says Patel.  

Related Content

J&J gains positive CHMP opinion for Rybrevant for treatment of lung cancer

Janssen, a Johnson & Johnson (J&J) company, has announced that the Committee for Medicinal Products …

FDA approves J&J’s Opsynvi for PAH treatment

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has …

Johnson & Johnson acquires Ambrx Biopharma for approximately $2bn

Johnson & Johnson (J&J) has announced that it has successfully completed its acquisition of Ambrx …

Latest content